182 related articles for article (PubMed ID: 8340941)
1. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes.
Fenton RG; Taub DD; Kwak LW; Smith MR; Longo DL
J Natl Cancer Inst; 1993 Aug; 85(16):1294-302. PubMed ID: 8340941
[TBL] [Abstract][Full Text] [Related]
2. Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli.
Fenton RG; Keller CJ; Hanna N; Taub DD
J Natl Cancer Inst; 1995 Dec; 87(24):1853-61. PubMed ID: 7494229
[TBL] [Abstract][Full Text] [Related]
3. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
4. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
5. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
Porgador A; Staats HF; Faiola B; Gilboa E; Palker TJ
J Immunol; 1997 Jan; 158(2):834-41. PubMed ID: 8993001
[TBL] [Abstract][Full Text] [Related]
6. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation.
Gjertsen MK; Bjorheim J; Saeterdal I; Myklebust J; Gaudernack G
Int J Cancer; 1997 Sep; 72(5):784-90. PubMed ID: 9311595
[TBL] [Abstract][Full Text] [Related]
8. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.
Peace DJ; Chen W; Nelson H; Cheever MA
J Immunol; 1991 Mar; 146(6):2059-65. PubMed ID: 2005390
[TBL] [Abstract][Full Text] [Related]
9. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
[TBL] [Abstract][Full Text] [Related]
10. T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.
Cheever MA; Chen W; Disis ML; Takahashi M; Peace DJ
Ann N Y Acad Sci; 1993 Aug; 690():101-12. PubMed ID: 8103658
[TBL] [Abstract][Full Text] [Related]
11. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
[TBL] [Abstract][Full Text] [Related]
12. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.
Abrams SI; Dobrzanski MJ; Wells DT; Stanziale SF; Zaremba S; Masuelli L; Kantor JA; Schlom J; Masuelle L [corrected to Masuelli L]
Eur J Immunol; 1995 Sep; 25(9):2588-97. PubMed ID: 7589131
[TBL] [Abstract][Full Text] [Related]
13. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
14. The induction of cytotoxic T cells and tumor regression by soluble antigen formulation.
Hariharan K; Braslawsky G; Black A; Raychaudhuri S; Hanna N
Cancer Res; 1995 Aug; 55(16):3486-9. PubMed ID: 7627951
[TBL] [Abstract][Full Text] [Related]
15. Mutant ras epitopes as targets for cancer vaccines.
Abrams SI; Hand PH; Tsang KY; Schlom J
Semin Oncol; 1996 Feb; 23(1):118-34. PubMed ID: 8607022
[TBL] [Abstract][Full Text] [Related]
16. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
[TBL] [Abstract][Full Text] [Related]
17. Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein.
Escobar P; Yu Z; Terskikh A; Holmes N; Corradin G; Mach JP; Healy F
Clin Exp Immunol; 1999 May; 116(2):214-9. PubMed ID: 10337009
[TBL] [Abstract][Full Text] [Related]
18. Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor.
Makki A; Weidt G; Blachere NE; Lefrançois L; Srivastava PK
Cancer Immun; 2002 Apr; 2():4. PubMed ID: 12747749
[TBL] [Abstract][Full Text] [Related]
19. Anti-T-cell humoral and cellular responses in healthy BALB/c mice following immunization with ovalbumin or ovalbumin-specific T cells.
Zhang XY; Liu XG; Wang W; Wang WC; Gao XM
Immunology; 2003 Apr; 108(4):465-73. PubMed ID: 12667208
[TBL] [Abstract][Full Text] [Related]
20. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide.
Chung SW; Cohen EP; Kim TS
Vaccine; 2004 Jun; 22(20):2547-57. PubMed ID: 15193380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
